-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Reiterates Outperform on Ascendis Pharma, Maintains $290 Price Target

Benzinga·11/13/2026 15:16:33
Listen to the news
RBC Capital analyst Luca Issi reiterates Ascendis Pharma (NASDAQ:ASND) with a Outperform and maintains $290 price target.